Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ultragenyx Pharma (RARE) PT Raised to $80 at Wedbush
August 6, 2018 7:50 AM EDTWedbush raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $80.00 (from $71.00) while maintaining a Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $90 at Stifel
August 3, 2018 9:35 AM EDTStifel raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $90.00 (from $77.00) while maintaining a Buy rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $85 at Piper Jaffray
August 3, 2018 6:01 AM EDTPiper Jaffray raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $85.00 (from $67.00) while maintaining a Overweight rating.
... More